BioMarin Q4 rev. down YoY; proposes acquisition of Amicus Therapeutics.

• BioMarin reports preliminary FY25 financials: total revenues $1.7 bln, VOXZOGO $457 mln • Expected asset write-down of $70 mln for ROCTAVIAN, impacting non-GAAP results • Proposed acquisition of Amicus Therapeutics expected to close by mid-2026 • BioMarin's proposed acquisition of Amicus Therapeutics aims to enhance strategic fit • Amicus' oculofacial dystrophy treatment, AMO-01, expected to launch in 2026 • BioMarin's digital data platform expected to integrate with Amicus' data and analytics capabilities • BioMarin's acquisition of Amicus is expected to expand its rare disease treatment portfolio.